technetium Tc 99m arcitumomab

01/01/1999 - "In a surgical decision-making analysis comparing CT, RIS (IMMU-4 99mTc-Fab'; CEA-Scan), and CT plus RIS in patients with recurrent or metastatic colorectal cancer, CT plus RIS improved correct prediction of resectability by 40% and correct prediction of unresectability by 100% compared with CT alone. "
09/01/2002 - "48 studies underwent to 45 patients (25 men and 20 women) with an average age of 64, diagnosed and treated of colorectal cancer, 5 hours after the intravenous administration of 1.25 mg of arcitumomab (CEA-scan) labelled with 945 MBq of 99mTc. "
03/01/2000 - "After reading this article, the nuclear medicine technologist will be able to: (a) describe the role of Arcitumomab in evaluating and managing patients with recurrent colorectal carcinoma metastasizing to the liver; (b) discuss the clinical use of CEA-Scan (Immunomedics, Inc., Morris Plains, NJ) and its overall imaging performance characteristics and sensitivity related to specific anatomical sites compared to conventional diagnostic modalities; (c) describe radiopharmaceutical preparation and quality control; (d) identify the pertinent patient history before starting the test; and (e) explain the imaging procedure, processing and display of data to optimize study interpretation."
12/01/1999 - "CEA-Scan (a 99mTclabeled Fab' fragment of a mouse mAb directed against CEA) has several advantageous properties, and has been approved for use in colorectal cancer SPECT imaging in North America and Europe, and is also under investigation in Japan. "
04/11/1997 - "22 patients, operated on for colorectal carcinoma and suspected of having a recurrence, underwent scintigraphy with CEA-scan and whole-body single-photon emission computed tomography (SPECT). "

08/01/1996 - "In 88 patients with occult cancer, imaging accuracy was enhanced significantly by CEA-Scan combined with CDM (61% v 33%). "
01/01/1997 - "Therefore, the current study evaluates the potential use of a new monoclonal antibody-based imaging agent, arcitumomab (CEA-Scan), which comprises an anti-carcinoembryonic antigen monoclonal antibody Fab' fragment labeled directly with technetium-99m, in the detection of primary, recurrent, or metastatic mammary cancer. "
03/01/1997 - "Cancer imaging with radiolabeled antibodies: new advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-Scan and prospects for therapy."

11/01/2000 - "Forty consecutive resected Dukes' B and C rectal cancer patients underwent a prospective, single-institution, surveillance trial of physical examination (including digital rectal examination), endoscopy, CT of the abdomen and pelvis, liver ultrasound, chest x-ray, blood CEA, and CEA immunoscintigraphy with arcitumomab (CEA-Scan, Immunomedics, Morris Plains, NJ) every 6 months for the first 2 years and every 12 months for the next 3 years after initial operation. "

01/01/1997 - "We investigated 20 patients-six with rectum-, 14 with colon cancer, 24 hours before surgery they were intravenously given 1 ml of an fab-fragment-antibody to CEA, labeled with 25mCi of 99mTc (CEA-Scan). "
12/01/2001 - "A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels."

02/01/2000 - "Detection of distant medullary thyroid carcinoma metastases by Tc-99m arcitumomab scintigraphy."